Synergy Pharmaceuticals Added to NASDAQ Biotechnology Index
5/14/2013 9:22:14 AM
More...
|
Synergy Pharmaceuticals Reports First Quarter 2013 Financial Results
5/10/2013 9:26:30 AM
More...
|
Synergy Pharmaceuticals' Chief Scientific Officer to Give Plenary Lecture on Plecanatide and SP-333 at the 15th Annual TIDES Summit
5/9/2013 9:29:53 AM
More...
|
Synergy Pharmaceuticals to Present Study Results From Plecanatide Phase IIb/III Trial in Late-Breaking Clinical Abstract at Digestive Disease Week 2013
3/15/2013 11:26:48 AM
More...
|
Synergy Pharmaceuticals Initiates Multiple Ascending Dose Phase Ib Trial in Healthy Volunteers of SP-333, a Second Generation Guanylate Cyclase C Agonist for the Treatment of Ulcerative Colitis
1/28/2013 9:16:40 AM
More...
|
Synergy Pharmaceuticals Announces Closing of Merger With Callisto Pharmaceuticals
1/18/2013 9:16:36 AM
More...
|
Callisto Pharmaceuticals Stockholders Approve Merger With Synergy Pharmaceuticals
1/15/2013 9:19:08 AM
More...
|
Synergy Pharmaceuticals' Constipation Drug Meets Study Goals
1/2/2013 7:03:23 AM
More...
|
Synergy Pharmaceuticals Begins Phase IIb Trial of Plecanatide in Irritable Bowel Syndrome With Constipation (IBS-C)
12/27/2012 9:12:40 AM
More...
|
Synergy Pharmaceuticals Presents Poster on Novel Mechanism of Action of SP-333, an Agonist of Guanylate Cyclase-C for Treatment of Ulcerative Colitis
12/14/2012 9:53:35 AM
More...
|
|